Board of Directors

Robert A Heft, PhD – Board Director

Dr. Heft is chief executive officer of ILIT BioVentures, an early stage company developing gene therapy for rare metabolic disorders. Dr. Heft is former president and CEO of Enobia Pharmaceuticals, Inc. In 2012, he sold Enobia to Alexion Pharmaceuticals Inc. for $1.1 Billion, the largest-ever sale of a private, pre-commercial biopharmaceutical company. Prior to Enobia, Dr. Heft held several senior positions with BioMarin Pharmaceutical Inc., Continental Pharma Cryosan, Inc. and IBEX Technologies, which he founded.

Thomas J. Miller – Board Director

Thomas Miller is the current founder of GreyBird Ventures, an umbrella company for consulting, investment, and management opportunities.  Prior to founding GreyBird Ventures, Mr. Miller served in numerous executive roles, most recently acting as CEO of the Customer Solutions Division at Siemens Healthcare where he was responsible for all downstream activities regarding healthcare, IT and new services for 26,000 employees in more 130 countries. Mr. Miller has been featured in Diagnostic Imaging magazine in its cover story on “The 20 Most Influential People in Diagnostic Radiology”.

Gene F. Pawlick, MD – Board Director

Dr. Pawlick was recently medical director at Kaiser Permanente Medical Group, Regional Reference Laboratories in Berkeley and Richmond, California. These laboratories comprise the largest reference clinical laboratory organization in the Kaiser Permanente system, performing more than 70 percent of all laboratory testing. At Kaiser Permanente, Dr. Pawlick pioneered clinical studies in the area of cancer screening and diagnosis and has participated in related hearings at the FDA as a field expert. He is Board Certified in Anatomic and Clinical Pathology.

Walter Robb, PhD – Board Director

Dr. Robb is currently a management consultant and president of Vantage Management, Inc. He serves on the board of Mechanical Technology, Inc., eight private, start-up companies and is a former Celgene board member. He previously served as senior vice president for General Electric’s Corporate Research and Development center, one of the world’s largest and most diversified industrial laboratories, and served on the company’s Corporate Executive Council. Additionally, he headed GE Medical Systems for 13 years.

Alan C. Nelson, PhD – Board Director

Dr. Nelson, is founder, chairman and CEO of VisionGate®. He is a physicist, bioengineer and entrepreneur who developed the world’s first and only automated screening test to detect cervical cancer, marketed today as FocalPoint by Becton Dickinson. He is former Executive Director of Arizona State University’s (ASU) Biodesign Institute and has held faculty positions at ASU, University of Washington, MIT and Harvard. Dr. Nelson holds more than 100 US patents and has more than 100 peer-reviewed publications in the field of biomedical imaging.

Sharon Everson, PhD– Board Director

Dr. Everson is president of Everson Design, which specializes in architectural design and construction management of single family custom homes, primarily in Washington. She previously worked as a numerical analyst at Massachusetts Institute of Technology (MIT). Additionally, she earned her doctorate degree in biophysics from UC Berkeley after receiving a degree in molecular biology from Yale. While at Yale, she was appointed a U.S. Presidential Scholar by the White House Commission on Presidential Scholars.

This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate® management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Contact Us

If you are interested in learning more about VisionGate and would like to speak with someone, please complete this short inquiry form and a representative will contact you as soon as possible.

Copyright 2018 - VisionGate, Inc.